Ready for tomorrow? "Mad Money" host Jim Cramer shares the two market themes that are key to making more money.» Read More
Investors Tuesday will again be watching for progress in the credit markets, where the trickle from a slow thaw has been enough to end the drought of buyers in the stock market.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
The Dow made another triple digit move on Monday this time soaring more than 400 points higher.
Stocks rallied to the finish line after another volatile session as signs began to emerge that credit markets may be defrosting. The Dow gained more than 400 points.
Stocks were higher in a wobbly session as investors digested remarks from Federal Reserve Chairman Ben Bernanke and Treasury Secretary Hank Paulson.
Despite a slowing economy, drug stocks such as Abbott Labs and Genentech posted positive earnings reports. Is health care the best defensive play in this market?
Following are the “Fast & Furious” trades - hot ways to play next week's market moving events.
A drug stock with a safe dividend? That's just what you need in this tough environment.
Some stocks are more popular than others. But that doesn't mean they're always the best shares to hold. Michael Farr, president of Farr, Miller and Washington, gave his assessment of five of the most widely held companies.
I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.
Since there should really be no compelling reason to blog or report on Dendreon and Provenge for quite awhile, here's one last hurrah.
Which stocks have been unfairly punished over the last three trading days?
Wall Street struggled with another day of selling as panic seemed to accelerate into the final minutes of trading.
Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).
As all eyes remain on Capitol Hill, things remain relatively quiet on the biopharma front. So, it's a good time to go through the Pharma's Market mailbag. The overwhelming majority of emails recently have been about...yeah, you guessed it...Dendreon.
Plus, should I own Pfizer?
The Dow closed lower on Wednesday as nervous investors found it difficult to muster enthusiasm ahead of the Senate’s vote on a revamped $700 billion rescue plan.
Eli Lilly has been running direct-to-doctor ads over the past few months telling physicians that Effient, the company's new bloodthinner, is "Coming Soon". Well, it may have jumped the gun.
Today is the day the FDA is expected to make a decision on the drug. The agency could approve it outright, approve it with conditions/limitations, delay making a decision--again--and order more tests, or reject the pill.
The Dow tumbled on Monday as investors worried a $700 billion bailout for the financial sector may not resuscitate a slumping economy...